Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Others

Insight Molecular Diagnostics (IMDX) Current Leases (2016 - 2023)

Insight Molecular Diagnostics' Current Leases history spans 1 years, with the latest figure at $628000.0 for Q4 2023.

On a quarterly basis, Current Leases changed N/A to $628000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $628000.0, a N/A change, with the full-year FY2023 number at $628000.0, changed N/A from a year prior.
Current Leases hit $628000.0 in Q4 2023 for Insight Molecular Diagnostics.
Over the last five years, Current Leases for IMDX hit a ceiling of $628000.0 in Q4 2023 and a floor of $628000.0 in Q4 2023.